Introduction and Objective: Individuals with type 2 diabetes (T2D) typically achieve attenuated weight loss with GLP-1 receptor agonists (GLP-1RAs). We investigated whether comprehensive digital health engagement improves weight loss trajectories in people with T2D initiating GLP-1RA therapy. Methods: This retrospective cohort included adults with T2D (18-75 years; BMI ≥30 kg/m² or ≥27.5 kg/m² with comorbidities) initiating tirzepatide or semaglutide through a UK digital weight management service (2022-2025) over 12 months. Patients were stratified by engagement. Full engagement was defined as remote coaching attendance, weight tracking ≥4/month, and app utilisation. Percentage weight change over 12 months was modelled using MMRM adjusted for age, baseline weight, and comorbidities. Cox regression assessed time to ≥10%, ≥15%, and ≥20% weight loss with hazard ratios (HR). Results: Among 7,642 adults with T2D (age 52.8±12.1 years; 71.8% female; BMI 36.9±7.0 kg/m²), 1,011 (13.2%) were fully engaged. Twelve-month adjusted weight loss was −19.5% (95% CI −20.4, −18.7) in engaged versus −14.6% (−15.2, −13.9) in not-engaged participants, a difference of 5.0 percentage points (p<0.001). Engagement was strongly associated with accelerated milestone attainment: ≥10% HR 2.44 (95% CI 2.22-2.69), ≥15% HR 2.18 (1.93-2.47), ≥20% HR 2.02 (1.70-2.41); all p<0.001. By month 12, 60.1% of engaged versus 29.0% of not-engaged participants achieved ≥10% weight loss, while 51.3% versus 21.1% achieved ≥15% weight loss. Conclusion: Full digital programme engagement yielded greater weight loss and doubled the likelihood of achieving clinically meaningful thresholds in people with T2D, demonstrating that structured digital support substantially improves GLP-1RA treatment outcomes in this population. Disclosure H. Johnson: Employee; Current; Voy t/a Menwell LTD. D. Reisel: Employee; Current; Voy t/a Menwell LTD. D. Huang: Employee; Current; Voy t/a Menwell LTD.
Introduction Solitary fibrous tumours of the pleura (SFTP) are rare neoplasms for which surgical resection is considered the gold standard treatment. Anecdotally, SFTPs are sometimes conservatively managed, but there are little data on this in published literature. In this study, we aimed to collect data on radiological features in SFTP which might be associated with a benign clinical course to assist in risk stratification, and therefore selection for a more conservative management pathway. Methods A service evaluation of outcomes of radiologically diagnosed SFTP was completed in 12 UK centres, between 2005 and 2015. Cases were included via initial search of local radiology databases using key words ("Pleural fibroma" OR "fibrous tumour of the pleura" OR "SFTP"). Baseline characteristics and outcome data were obtained from medical records. Results A total of 270 patients were included in the study. Factors associated with the need for surgical intervention included lesion size (>128 mm), lesion position (abutting the mediastinum or diaphragm), associated pleural effusion, radiological evidence of necrosis within the lesion and heterogeneous density. In multivariate analysis, computed tomography-measured attenuation and homogeneous density were independent risk factors for adverse clinical outcomes in patients with resected fibromas. Conclusion This is the largest study to date on SFTP to include conservatively managed cases who underwent radiological follow-up only. The results suggest several features associated with adverse clinical outcomes, and thereby may identify cases which could be more conservatively (observation only) managed. Further prospective studies are required to assess the identified risk factors as part of a potential radiological scoring system.
Objective To compare the real-world safety profiles of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) in patients with diffuse large B-cell lymphoma, leveraging data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Patients and Methods Case reports submitted to FAERS (Q4 2017 to Q3 2024) were evaluated if liso-cel or axi-cel was identified as the primary suspect therapy for adverse events of interest such as cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), cytopenia, and infections. Disproportionality analyses compared AE frequencies using reporting odds ratios (ROR). Concomitant treatment use rates were captured to assess the need for supportive medications. Results Among 3251 diffuse large B-cell lymphoma-related reports, liso-cel was the primary therapy in 232 cases compared with 3019 attributed to axi-cel. Liso-cel had significantly lower RORs (95% CI) for CRS (0.68; 0.52-0.89), ICANS (0.62; 0.47-0.82), and cytopenia (0.41; 0.24-0.71) vs axi-cel; infection rates were similar (0.73; 0.40-1.33). Fewer patients used concomitant treatments with liso-cel than axi-cel (49 [21.1%] vs 1019 [33.8%]; P<.001), particularly corticosteroids, azoles, and levetiracetam. Tocilizumab use was similar (8 [3.5%] liso-cel vs 97 [3.2%] axi-cel), and intravenous immunoglobulin use was rare (<1%). Conclusion Liso-cel reported a more favorable safety profile than axi-cel, with fewer reports of CRS, ICANS, cytopenia, and the need for supportive medications. Although efficacy outcomes were not analyzed, safety outcomes are consistent with previously published indirect treatment comparisons and can inform evidenced-based decision-making of clinicians.
